Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Xeljanz (tofacitinib) and Otezla (apremilast) are both oral medications used to treat inflammatory conditions, but they belong to different drug classes and have distinct uses and side effects. Xeljanz is a Janus kinase (JAK) inhibitor that treats various types of arthritis and ulcerative colitis by blocking a protein involved in inflammation. In contrast, Otezla is a phosphodiesterase-4 (PDE-4) inhibitor that blocks a different protein to reduce inflammation associated with psoriatic arthritis, plaque psoriasis, and mouth sores from Behçet’s disease. Xeljanz can cause serious side effects like infections, heart problems, and blood clots, while Otezla is more likely to cause nausea, diarrhea, and weight loss. Both medications are not yet available as lower-cost generics. Xeljanz is available in both immediate-release and extended-release forms. And Otezla is only available in one formulation that requires a gradual dose increase to minimize stomach-related side effects.
Xeljanz (tofacitinib)
Otezla (apremilast)
Xeljanz (tofacitinib)
Otezla (apremilast)
Summary of Xeljanz vs. Otezla
Summary for JAK inhibitor
Prescription only
Xeljanz (tofacitinib) is an oral medication that can treat different inflammatory problems. It can help adults with psoriatic arthritis, rheumatoid arthritis (RA), and ulcerative colitis, among other conditions. It's also helpful for children with a certain kind of arthritis. Xeljanz (tofacitinib) is a JAK inhibitor that lowers inflammation in the body. It comes as a tablet or liquid that's taken twice a day. There's also a longer-lasting once-daily tablet for adults. Xeljanz (tofacitinib) is a good option for people who've tried other medications first. But it can have side effects like headache, diarrhea, and a higher risk of infection. This medication is brand name only; there isn't a generic yet.
Summary for PDE-4 inhibitor
Prescription only
Otezla (apremilast) is a tablet that's taken by mouth. It treats plaque psoriasis and psoriatic arthritis in people 6 years and older. The medication can also treat mouth sores from Behçet’s disease in adults. It works as a phosphodiesterase-4 (PDE4) inhibitor to reduce inflammation. Immediate-release tablets called Otezla are taken twice daily. You start at a low dose, then it gets raised over a few days to a maintenance dose. Some people can switch to once-daily, extended-release tablets called Otezla XR. Side effects include nausea and diarrhea.
•Moderate-to-severe polyarticular course juvenile idiopathic arthritis (pcJIA) in children 2 years and older - immediate-release tablets and liquid only